大肠癌患者血清CD147和MMP-2水平的变化及意义

目的检测细胞外基质金属蛋白酶诱导因子（EMMPRIN，又称CD147）和基质金属蛋白酶-2（MMP-2）在大肠癌血清中的水平，探讨其与大肠癌恶性程度、侵袭和转移的关系及其相互联系。方法应用酶联免疫吸附实验（ELISA）方法测定44例大肠癌、28例大肠息肉和36例健康对照者血清中CD147和MMP-2的水平。结果大肠癌患者组血清CD147（103．59±40．74）pg／ml和MMP-2（14．92±2．02）ng／ml水平明显高于大肠息肉组（66．27±16．91；10．96±1．71）和健康对照组（63．84±18．71；10．49±1．61）（P〈0．05），差异有统计学意义；大肠癌患者中伴转移组血清中CD147水平显著高于无转移组（P〈0．05），大肠癌患者低分化组血清中MMP-2水平显著高于高，中分化组（P〈0．05），大肠癌患者根治性手术组术后1个月CD147和MMP-2水平明显下降（P〈0．05），而姑息性手术组虽有下降但不显著（P〉0．05）。大肠癌患者血清CD147和MMP-2水平呈正相关（r=0．61，P〈0．05）。结论大肠癌患者血清CD147和MMP-2水平增高，与肿瘤的组织分化程度、转移、分期有关，动态观察血清CD147和MMP-2水平的变化可作为大肠癌的诊断、手术方法的选择、疗效评价及预后监测有意义的参考指标。

Serum CD147 and MMP-2 levels in patients with colorectal cancer and their significance

Objective To investigate the serum levels of CD147 and MMP-2 and the relationship between these proteins and colorectal tumor differentiation, Dukes stage. Methods Serum levels of CD147 and MMP-2 in 44 patients with colorectal carcinoma,28 polyp intestinal patients and 36 normal subjects were measured by ELISA. Results Serum levels of CD147(103.59±40.74pg/ml)and MMP-2(14.92±2.02ng/ml)in the cancer patients were significantly higher than those of the polyp intestinal(66.27±16.91;10:96±1.71)and normal control(63.84±18.71;10.49±1.61)(P＜0.05).The levels were associated with tumor differentiation and Dukes stage. Patients with poor differentiation had significantly higher levels of MMP-2 than those of patients with well differentiation. And Dukes C and D stage tumors had significantly higher levels of CD147 than Dukes A and B stage tumors(P＜0.05).The levels of CD147 and MMP-2 declined remarkably after one month of radical operation. Conversely, it decreased illegibly after palliative operation. The serum levels of CD147were positively correlated with MMP-2 in patients with colorectal cancer. Conclusion Elevated CD147 and MMP-2 serum levels are associated with tumor differentiation, invasion, metastasis. Dynamic alterations of serum CD147 and MMP-2 may be used as the indicators of diagnosis, the choice of operative method and the judgment of prognosis in patients with colorectal cancer.